| Literature DB >> 22405031 |
Bodil Arnbak1, Charlotte Leboeuf-Yde, Tue Secher Jensen.
Abstract
INTRODUCTION: Magnetic resonance imaging (MRI) has been proven capable of showing inflammatory and structural changes in patients with spondyloarthritis (SpA) and has become widely used in the diagnosis of SpA. Despite this, no systematic reviews evaluate the diagnostic utility of MRI for SpA. Therefore, the objective of this systematic review was to determine the evidence for the utility of MRI in the clinical diagnosis of SpA. The aims were to identify which MRI findings are associated with the diagnosis of SpA and to quantify this association.Entities:
Mesh:
Year: 2012 PMID: 22405031 PMCID: PMC3446421 DOI: 10.1186/ar3768
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Quality scores for the articles on MRI and SpA fulfilling the inclusion criteria
| 1 | 0 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | |
| 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | |
| 0 | 0 | 0 | 2 | 2 | 1 | 2 | 2 | 1 | |
| 0 | 1 | 1 | 2 | 0 | 1 | 2 | 1 | 1 | |
Diagnosis assessed on IBP or SpA diagnosed by criteria (best) or expert opinion (second best), same diagnosis performed on whole sample, diagnosis independent of MRI, diagnosis blinded for MRI, and reproducibility of diagnosis tested (inter- and intraexaminer reliability tested and reported). MRI evaluation assessed on clear definition of each relevant MRI finding, MRI blinded from diagnosis, reproducibility (inter- and intraexaminer reliability tested and reported), and short time between the MRI scan and diagnosis. Data analysis and presentation of results assessed on statistical significance test and confidence intervals reported where relevant and results presented in an understandable way. 0, Nonacceptable; 1, Reasonable; 2, Good; SpA, spondyloarthritis; IBP, inflammatory back pain.
Figure 1Flow chart of the review process.
Reasons for excluding retrieved articles on cross-sectional studies
| Study | Reasons for exclusion |
|---|---|
| Ahlstrom H, | < 20 controls |
| Algin O, | < 20 controls |
| Algin O, | < 20 controls |
| Baraliakos X, | No controls |
| Bejia I, | < 20 cases |
| Blum U, | Field strength, < 1.5 Tesla |
| Bochkova AG, | No controls |
| Bollow M, | Double publication on Bollow |
| Bollow M, | Double publication on Bollow |
| Bozgeyik Z, | No controls |
| Braun J, | < 20 controls |
| Braun J, | Reference standard (HLA-B27 status) not a clinical diagnosis |
| Bredella MA, | No controls |
| Chung H Y, | No controls |
| Docherty P, | < 20 controls |
| Friedburg H, | No controls |
| Gleeson TG, | < 20 cases |
| Gupta AD, | < 20 controls |
| Hanly JGJ, | < 20 controls |
| Heuft-Dorenbosch L, | Reference standard (plain radiographic) not a clinical diagnosis |
| Heuft-Dorenbosch L, | No controls |
| Heuft-Dorenbosch L, | No controls |
| Inanc N, | Reference standard (plain radiographic) not a clinical diagnosis |
| Jevtic V, | No controls |
| Liao Z, | No MRI of the control group |
| Liao Z, | No controls |
| Luukkainen RK, | No controls |
| Marc V, | < 20 controls |
| McNally EG, | < 20 cases |
| Muche B, | No controls |
| Murphey MD, | < 20 controls |
| Orchard TR, | < 20 cases |
| Peterova V | No controls |
| Puhakka KB, | No controls |
| Remy, | No controls |
| Rennie WJ, et al. (2009) [ | < 20 controls |
| Rudwaleit M, | < 20 controls |
| Rudwaleit M, | Insufficient result presentation |
| Rudwaleit M, | Insufficient result presentation |
| Sreedhar C, | < 20 cases |
| Weber U, | < 20 controls |
| Weber U, | Double publication on Weber |
| Wecbach | No controls |
| Wienands K, | No controls |
| Williamson L, | Reference standard (orthopedic test) not a clinical diagnosis |
| Wittram C, | < 20 controls |
| Wittram C, | < 20 controls |
| Yu W, | < 20 controls |
Studies may have met exclusion criteria other than those listed in the table. MRI, magnetic resonance imaging.
Reasons for excluding retrieved articles on longitudinal studies
| Study | Reasons for exclusion |
|---|---|
| Althoff CE, | Insufficient result presentation |
| Aydin SZ, | < 20 controls |
| Baraliakos X, | No controls |
| Battafarano DF, | < 20 controls |
| Bennett AN, | No controls |
| Bigot J, | < 20 control |
| Brandt J, | No controls |
| Chiowchanwisawakit P, | No controls |
| Dougados M, | Insufficient result presentation |
| Hermann J, | Insufficient result presentation |
| Madsen K, | No controls |
| Macsymowych WP, | No controls |
| Marzo-Ortega H, | < 20 in each control group |
| Oostveen J, | No controls |
| Pedersen SJ, | No controls |
| Puhakka KB, | No controls |
| Remplik P, | < 20 cases |
| Shankar S, | Insufficient result presentation |
| Song IH, | No controls |
Studies may have met exclusion criteria other than those listed in the table.
Descriptive data for articles on MRI and SpA fulfilling the inclusion criteria
| Study type | Total number | Number of AS patients (DD) | Number of SpA patients (DD) | Number of IBP patients (DD) | Number of NILBP patients (DD) | Number of no LBP patients | |
|---|---|---|---|---|---|---|---|
| Bollow | Prospective case-control | 125 | 36 (3.1 years) | 36 (5.9 years) | 53 (5.7 years) | ||
| Klauser | Prospective case-control | 133 | 103 (NR) | 30 | |||
| Brandt | Prospective cohort | 158 | 32 (NR) | 58 (NR) | 68 (NR) | ||
| Weber | Prospective case-control | 187 | 75 (6.1 years) | 27 (29 mo) | 26 (NR) | 59 | |
| Wick | Retrospective cohort | 156 | 27 (NR) | 101 (NR) | 28 (NR) | ||
| Kim | Retrospective case control | 104 | 52 (NR) | 52 (NR) | |||
| Weber | Prospective case-control | 85 | 35 (8 years) | 25 (10 mo) | 35 | ||
| Bennett | Retrospective cohort | 185 | 64 (8.5 years) | 110 (NR) | 11 | ||
| Bennett | Retrospective cohort | 185 | 64 (8.5 years) | 110 (NR) | 11 | ||
MRI, magnetic resonance imaging; SpA, spondyloarthritis; AS, ankylosing spondylitis; DD, mean disease duration;
IBP, inflammatory back pain; NILBP, noninflammatory low-back pain; no LBP, no low-back pain; mo, months; NR, mean disease duration not reported.
Descriptive data for MRI technique used in the included articles
| Field strength | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 | |
|---|---|---|---|---|---|---|---|
| Bollow | 1.5 T | Semi axial T1w SE | Dynamic T2*w GRE, FLASH, | Dynamic T2*w GRE, FLASH, Gd | |||
| Klauser | 1.5 T | Semi axial T1w, SE | Semi axial T2 w TSE | Semi axial T1w, SE FS | Semi cor. T1w, SE | Semi cor. TIRM | Semi axial + Semi cor. T1w, SE, FS, Gd |
| Brandt | a1.5 T | NR | |||||
| Weber | a1.5 T | Semi cor. T1 w, SE | Semi cor. STIR | ||||
| Wick | 1.5 T | Semi cor. T1 w, SE | Semi cor. TIRM | Semi cor. T2w, MEDIC FS | Semi cor. + semi axial T1w, SE, FS | Semi axial T1w, SE, FS, Gd | Semi axial T1w, SE, Gd |
| Kim | 1.5 T | Sagittal T1w SE | Sagittal T2w FSE | ||||
| Weber | 1.5 T | Sagittal turbo STIR | |||||
| Bennett | a1.5 T | Sagittal T1, SE | Sagittal STIR | ||||
| Bennett | a1.5T | Sagittal T1w, SE | Sagittal STIR | ||||
aInformation on field strength not available in the articles. Data obtained by personal contact with authors. T, Tesla; w, weighted; SE, spin-echo; GRE, gradient-echo; FLASH, fast low-angle shot; Semi cor, semicoronal; Gd, gadolinium; TSE, turbo spin-echo; FS, fat saturated; TRIM, turbo inversion recovery magnitude; NR, not reported; STIR, short tau inversion recovery; MEDIC, multi echo data image combination; PD, proton density; FSE, fast spin echo.
Associations between MRI finding in the SIJ and the diagnosis of AS and IBP
| MRI findings | Sensitivity of MRI findings | Specificity of MRI findings | Cases, number | Controls, number | ||
|---|---|---|---|---|---|---|
| AS | IBP | NLSBP | No LBP | |||
| BMO | 0.85 (0.76-0.92) | 0.93 (0.84-0.97) | 75 | 59 | ||
| Erosions | 0.91 (0.82-0.95) | 0.98 (0.91-1.00) | 75 | 59 | ||
| Fat infiltration | 0.91 (0.82-0.95) | 0.86 (0.76-0.93) | 75 | 59 | ||
| Ankylosis | 0.27 (0.18-0.38) | 1.00 (0.94-1.00) | 75 | 59 | ||
| Global assessment | 0.99 | 0.96 | 75 | 59 | ||
| BMO | 0.85 (0.76-0.92) | 0.77 (0.58-0.89) | 75 | 26 | ||
| Erosions | 0.91 (0.82-0.95) | 0.96 (0.81-0.99) | 75 | 26 | ||
| Fat infiltration | 0.91 (0.82-0.95) | 0.85 (0.67-0.94) | 75 | 26 | ||
| Ankylosis | 0.26 (0.18-0.38) | 1.00 (0.87-1.00) | 75 | 26 | ||
| Global assessment | 0.99 | 0.92 | 75 | 26 | ||
| BMO | 0.67 (0.48-0.81) | 0.93 (0.84-0.97) | 27 | 59 | ||
| Erosions | 0.48 (0.31-0.66) | 0.98 (0.91-1.00) | 27 | 59 | ||
| Fat infiltration | 0.37 (0.22-0.56) | 0.86 (0.76-0.93) | 27 | 59 | ||
| Global assessment | 0.52 | 0.96 | 27 | 59 | ||
| BMO | 0.67 (0.48-0.81) | 0.77 (0.58-0.89) | 27 | 26 | ||
| Erosions | 0.48 (0.31-0.66) | 0.96 (0.81-0.99) | 27 | 26 | ||
| Fat infiltration | 0.37 (0.22-0.56) | 0.85 (0.67-0.94) | 27 | 26 | ||
| Global assessment | 0.52 | 0.92 | 27 | 26 | ||
Results from Weber et al. (2010). Sensitivity and specificity based on concordant observations of a minimum of two of five readers. 95% CI calculated from raw data. MRI, magnetic resonance imaging; SIJ, sacroiliac joint; AS, ankylosing spondylitis; IBP, inflammatory back pain; CI, confidence interval; NSLBP, nonspecific low-back pain; BMO, bone marrow edema; global assessments, 95% CI not possible to calculate, because of no raw data.
Associations between MRI finding in the spine and the diagnosis of AS and IBP
| MRI findings | Sensitivity of MRI findings | Specificity of MRI findings | Cases, number | Controls, number | |
|---|---|---|---|---|---|
| AS | IBP | No LBP | |||
| ≥ 1 CIL | 0.77 (0.61-0.88) | 0.77 (0.61-0.88) | 35 | 35 | |
| ≥ 2 CIL | 0.69 (0.52-0.81) | 0.94 (0.81-0.98) | 35 | 35 | |
| ≥ 3 CIL | 0.66 (0.49-0.79) | 0.94 (0.81-0.98) | 35 | 35 | |
| ≥ 1 tCIL | 0.69 (0.52-0.81) | 0.83 (0.67-0.92) | 35 | 35 | |
| ≥ 2 tCIL | 0.57 (0.41-0.72) | 0.94 (0.81-0.98) | 35 | 35 | |
| ≥ 3 tCIL | 0.46 (0.30-0.62) | 0.97 (0.85-0.99) | 35 | 35 | |
| ≥ 1 lCIL | 0.51 (0.36-0.67) | 0.94 (0.81-0.98) | 35 | 35 | |
| ≥ 1 NIL | 0.06 (0.02-0.19) | 0.97 (0.85-0.99) | 35 | 35 | |
| ≥ 1 LIL | 0.31 (0.19-0.48) | 0.97 (0.85-0.99) | 35 | 35 | |
| ≥ 1 FIL/PIL | 0.09 (0.03-0.22) | 1.00 (0.90-1.00) | 35 | 35 | |
| ≥ 1 CIL | 0.40 (0.23-0.59) | 0.88 (0.70-0.96) | 25 | 25 | |
| ≥ 2 CIL | 0.32 (0.17-0.52) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 3 CIL | 0.12 (0.04-0.30) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 1 tCIL | 0.32 (0.17-0.52) | 0.88 (0.70-0.96) | 25 | 25 | |
| ≥ 2 tCIL | 0.24 (0.11-0.43) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 3 tCIL | 0.12 (0.04-0.30) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 1 lCIL | 0.24 (0.11-0.43) | 1.00 (0.87-1.00) | 25 | 25 | |
| ≥ 1 NIL | 0.04 (0.01-0.20) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 1 lCIL | 0.12 (0.04-0.30) | 0.96 (0.80-0.99) | 25 | 25 | |
| ≥ 1 FIL/PIL | 0.00 (0.00-0.13) | 1.00 (0.87-1.00) | 25 | 25 | |
Sensitivity and specificity based on concordant observations of three readers; results from Weber et al. (2009). AS, Ankylosing spondylitis; IBP, inflammatory back pain; no LBP, no low-back pain; CIL, vertebral corner inflammatory lesion; tCIL, thoracic CIL; lCIL lumbar CIL; NIL, vertebral noncorner inflammatory lesion; LIL, lateral inflammatory lesion; FIL/PIL, facet or other posterior element inflammatory lesion.